RonaldHYanagiharaMD

PubMed

• 10 citations
  A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer...
  Athanassios Argiris, Jieling Miao, Mihaela C. Cristea, Allen M. Chen, Jacob Sands, Roy H. Decker, Scott N. Gettinger, Megan E. Daly, Bryan A. Faller, Kathy S. Albain, ...> ;Clinical Lung Cancer. 2021 Feb 19
• 6 citations
  STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib.
  Misako Nagasaka, Nagaratna Sarvadevabatla, Shawn Iwata, Yubin Ge, Ammar Sukari, Christian Klosowski, Ronald Yanagihara> ;JTO Clinical and Research Reports. 2021 Feb 1
• 16 citations
  Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phas...
  Gabrail, N., Yanagihara, R., Spaczyński, M., Cooper, W., O'Boyle, E., Smith, C., Boccia, R.> ;Cancer management and research. 2015 Apr 4
• 40 citations
  XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treat...
  M. Catherine Pietanza, Thomas J. Lynch, Primo N. Lara, John Cho, Ronald H. Yanagihara, Nandagopal Vrindavanam, Naveed Chowhan, Shirish M. Gadgeel, Nathan A. Pennell, R...> ;Journal of Thoracic Oncology. 2012 Jan 1
• 23 citations
  A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
  Alexander I. Spira, Nicholas Iannotti, Michael Savin, Marcus A. Neubauer, Nashat Y. Gabrail, Ronald H. Yanagihara, Edith A. Zang, Patricia E. Cole, Dale E. Shuster, As...> ;Clinical Lung Cancer. 2012 Jan 1
• Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).
  Grous JJ, Riegel E, Gabrail N, Charu V, Arevalo-Araujo R, Yanagihara R, Nguyen A, Robertson P, Cooper B, O'Boyle E, Barr J> ;J. Clin. Oncol.. 2009-05-20
• Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial.
  Miller VA, Wakelee HA, Lara PN, Cho J, Chowhan NM, Costa D, Vrindavanam N, Yanagihara R, Pennell N, Lynch TJ> ;J. Clin. Oncol.. 2008-05-20
• 48 citations
  Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
  Heinz Joseph Lenz, F. C. Lee, Daniel G. Haller, D. A. Singh, Al B. Benson, Dirk Strumberg, Ronald Yanagihara, James C. Yao, Alexandra T. Phan, Jaffer A. Ajani> ;Cancer. 2007 Jan 1
• Extended safety and efficacy data on S-1 plus cisplatin in patients with advanced gastric carcinoma in a multi-center phase II study.
  Lenz H, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara RH, Yao JC, Phan AT, Ajani JA> ;J. Clin. Oncol.. 2006-06-20
• 78 citations
  Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients With Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
  J. A. Ajani, F. C. Lee, D. A. Singh, D. G. Haller, Heinz-Josef Lenz, Al B. Benson, Ronald Yanagihara, Alexandria T. Phan, James C. Yao, Dirk Strumberg> ;Journal of Clinical Oncology. 2006 Feb 1
• Multi-center phase II study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC).
  Ajani JA, Phan A, Yao JC, Lee F, Singh DA, Haller D, Benson AB, Lenz H, Yanagihara RH, Strumberg D> ;J. Clin. Oncol.. 2005-06-01
• 59 citations
  Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy
  Charles L. Vogel, Ronald H. Yanagihara, Albert J. Wood, Frederick M. Schnell, Charles Henderson, Barry H. Kaplan, Malcolm H. Purdy, Richard Orlowski, Jodi L. Decker, L...> ;The Oncologist. 2004 Nov 1
• Safety of zoledronic acid in patients who have previously received bisphosphonate therapy.
  Yanagihara R, Vogel CL, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker J, Lacerna L> ;J. Clin. Oncol.. 2004-07-15
• 484 citations
  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a random...
  Lee S. Rosen, David Gordon, N. Simon Tchekmedyian, Ronald Yanagihara, Vera Hirsh, Maciej Krzakowski, Marek Pawlicki, Paul de Souza, Ming Zheng, Gladys Urbanowitz, Dirk...> ;Cancer. 2004 Jun 15
• 518 citations
  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial...
  Lee S. Rosen, David Gordon, Simon Tchekmedyian, Ronald Yanagihara, Vera Hirsh, Maciej Krzakowski, Marek Pawlicki, Paul de Souza, Ming Zheng, Gladys Urbanowitz, Dirk J....> ;Journal of Clinical Oncology. 2003 Aug 15
• 11 citations
  Two Biochemical Markers Effectively Used to Separate Smokeless Tobacco Users From Smokers and Nonusers
  David B. Holiday, Jerry McLarty, Ronald Yanagihara, Lynda Riley, Sara Shepherd> ;Southern Medical Journal. 1995 Aug 31
• 14 citations
  A novel morphine sulphate preparation: clinical trial of a controlled-release morphine suspension in cancer pain:
  Walter B. Forman, Russell K. Portenoy, Ronald H Yanagihara, Curtis Hunt, Rebecca Kush, Kirk Shepard> ;Palliative Medicine. 1993 Oct 1
• 78 citations
  Beta-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study.
  Jerry W. McLarty, David B. Holiday, W M Girard, R H Yanagihara, T D Kummet, S D Greenberg> ;The American Journal of Clinical Nutrition. 1995 Dec 1
• Join now to see all